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Background
Human xenograft tumor models are widely used for eval-
uation of potential cancer targets, by assessing the anti-
tumor effects of specific agents, such as siRNA. siRNA is
usually stably introduced into tumor cells prior to trans-
plantation. However, oncogene silencing results in
reduced cell growth/survival in vitro and/or failure to
establish tumors in vivo, thus hindering tumor response-
based efficacy evaluation that is more clinically relevant.
We therefore explored a new tumor response model based
on regulated RNAi.
Methods
A unique RNAi vector was generated to express shRNA
only after induction with doxycylcine. Using this vector,
we created a novel xenograft tumor model, in which
tumors are established under non-induced conditions,
followed by induced target inactivation upon oral dosing
of the inducer. Three genes were evaluated, a known onco-
gene (mTOR), and two novel cancer targets (HE7 and
HE26), by assessing the tumor response to their silencing.
Results
We demonstrate a significant response of staged tumor
regression to silencing of all three target genes. For early
staged tumors, inactivation of each of the three targets
caused dramatic tumor regression (100% regressed and
50% became tumor-free for both mTOR and HE7, and
100% for HE26). Advanced staged tumors also demon-
strated significant responses (100% regression for mTOR,
and 75% for HE7, 85% HE26).
Conclusion
Our results demonstrate the utility of this unique and
powerful model for efficacy evaluation of cancer targets;
our data also provide robust in vivo efficacy validations of
HE7 and HE26 as novel cancer therapeutic targets.
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